2. Search Result
Search Result
Results for "

urine sodium excretion

" in MedChemExpress (MCE) Product Catalog:

34

Inhibitors & Agonists

3

Peptides

8

Natural
Products

7

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W015466
    Acetylvaline

    		Endogenous Metabolite Metabolic Disease
    Acetylvaline is an amino acid derivative belonging to the N-acetylated amino acid family. Acetylvaline can be detected in small quantities in the urine of healthy individuals but shows significantly abnormal excretion in the urine of patients with maple syrup urine disease (MSUD). Acetylvaline can be used to detect MSUD .
    Acetylvaline
  • HY-113409
    3-Hydroxyisovaleric acid
    1 Publications Verification

    		 Endogenous Metabolite Metabolic Disease
    3-Hydroxyisovaleric acid is a normal endogenous metabolite excreted in the urine. The urinary excretion of 3-hydroxyisovaleric acid is early and sensitive indicator of biotin deficiency .
    3-Hydroxyisovaleric acid
  • HY-B0235
    Trichlormethiazide
    2 Publications Verification

    		 Carbonic Anhydrase Metabolic Disease
    Trichlormethiazide is an orally active thiazide diuretic, with antihypertensive effect. Trichlormethiazide increases urine volume (UV), Na and K excretion and tends to improve the depressed creatinine clearance (CCRE) in acute renal failure rats model .
    Trichlormethiazide
  • HY-114961
    15-epi Prostaglandin A1

    15-epi PGA1

    		 Prostaglandin Receptor Cardiovascular Disease
    15-epi Prostaglandin A1 (15-epi PGA1) is the 15(R) stereoisomer of PGA1. PGA1 causes renal vasodilation, increased urine sodium excretion, and decreased arterial pressure in hypertensive models .
    15-epi Prostaglandin A1
  • HY-129557
    A-49816

    		Vasopressin Receptor Neurological Disease
    A-49816 is an orally active diuretic that increases urine volume and sodium and chloride excretion. A-49816 at high doses (12.5, 15, and 20 mg) caused significant salt and chloride excretion and diuresis in experimental animals .
    A-49816
  • HY-N11562
    Aristololactam II

    		Others Others
    Aristololactam II, a metabolite of Aristolochic acid II (AAII), is an excretion product found in the urine, which is considered to be detoxification metabolite of AAII .
    Aristololactam II
  • HY-W015466S
    Acetylvaline-15N

    		Endogenous Metabolite Metabolic Disease
    Acetylvaline- 15N is the 15N-labeled Acetylvaline (HY-W015466). Acetylvaline is an amino acid derivative belonging to the N-acetylated amino acid family. Acetylvaline can be detected in small quantities in the urine of healthy individuals but shows significantly abnormal excretion in the urine of patients with maple syrup urine disease (MSUD). Acetylvaline can be used to detect MSUD.
    Acetylvaline-15N
  • HY-W015466R
    Acetylvaline (Standard)

    		Endogenous Metabolite Metabolic Disease
    Acetylvaline (Standard) is an analytical standard for acetylvaline (HY-W015466). This product is intended for research and analytical applications. Acetylvaline is an amino acid derivative that belongs to the N-acetylated amino acid family. Acetylvaline is detected in low levels in the urine of healthy individuals, but significant abnormal excretion is observed in the urine of individuals with maple syrup urine disease (MSUD). Acetylvaline can be used to detect MSUD.
    Acetylvaline (Standard)
  • HY-W015466S1
    Acetylvaline-13C2

    		Isotope-Labeled Compounds Endogenous Metabolite Metabolic Disease
    Acetylvaline-13C2 is the 13C-labeled Acetylvaline (HY-W015466). Acetylvaline is an amino acid derivative belonging to the N-acetylated amino acid family. Acetylvaline can be detected in small quantities in the urine of healthy individuals but shows significantly abnormal excretion in the urine of patients with maple syrup urine disease (MSUD). Acetylvaline can be used to detect MSUD.
    Acetylvaline-13C2
  • HY-120147
    Ethiazide

    		Natriuretic Peptide Receptor (NPR) Cardiovascular Disease
    Ethiazide is a thiazole diuretic which inhibits renal reabsorption of sodium and water, thereby increasing urine excretion, reducing fluid retention, and lowering blood volume and blood pressure. Ethiazide can be used for cardiovascular research .
    Ethiazide
  • HY-B0235A
    Trichlormethiazide sodium

    		Carbonic Anhydrase Metabolic Disease
    Trichlormethiazide sodium is an orally active thiazide diuretic, with antihypertensive effect. Trichlormethiazide sodium increases urine volume (UV), Na and K excretion and tends to improve the depressed creatinine clearance (CCRE) in acute renal failure rats model .
    Trichlormethiazide sodium
  • HY-W041019
    5-Hydroxytryptophol

    		Endogenous Metabolite Metabolic Disease
    5-Hydroxytryptophol is a mammalian serotonin metabolite that can be used as a sensitive biomarker for recent alcohol intake. 5-Hydroxytryptophol is formed by alcohol-induced changes in the serotonin metabolic pathway and is excreted in the urine as a glucuronic acid conjugate. 5-Hydroxytryptophol is elevated in urine excretion and can be used clinically to monitor alcohol intake in scenarios such as alcohol relapse .
    5-Hydroxytryptophol
  • HY-W041019R
    5-Hydroxytryptophol (Standard)

    		Endogenous Metabolite Metabolic Disease
    5-Hydroxytryptophol is a mammalian serotonin metabolite that can be used as a sensitive biomarker for recent alcohol intake. 5-Hydroxytryptophol is formed by alcohol-induced changes in the serotonin metabolic pathway and is excreted in the urine as a glucuronic acid conjugate. 5-Hydroxytryptophol is elevated in urine excretion and can be used clinically to monitor alcohol intake in scenarios such as alcohol relapse .
    5-Hydroxytryptophol (Standard)
  • HY-113409R
    3-Hydroxyisovaleric acid (Standard)

    		Reference Standards Endogenous Metabolite Metabolic Disease
    3-Hydroxyisovaleric acid (Standard) is the analytical standard of 3-Hydroxyisovaleric acid. This product is used for research and analytical applications. 3-Hydroxyisovaleric acid is a normal endogenous metabolite excreted in urine. The urinary excretion of 3-Hydroxyisovaleric acid serves as an early and sensitive indicator of biotin deficiency .
    3-Hydroxyisovaleric acid (Standard)
  • HY-10450
    Dapagliflozin
    Maximum Cited Publications
    57 Publications Verification

    BMS-512148

    		 SGLT Metabolic Disease Cancer
    Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin induces HIF1 expression and attenuates renal IR injury .
    Dapagliflozin
  • HY-113465
    Leukotriene E4

    LTE4

    		 Endogenous Metabolite Inflammation/Immunology
    Leukotriene E4 (LTE4) is produced by the action of dipeptidase on LTD4. Leukotriene E4 is one of the constituents of slow-reacting substance of anaphylaxis (SRS-A). Leukotriene E4 accumulates in both plasma and urine and urinary excretion of Leukotriene E4 is most often used as an indicator of asthma.
    Leukotriene E4
  • HY-B0235R
    Trichlormethiazide (Standard)

    		Carbonic Anhydrase Reference Standards Metabolic Disease
    Trichlormethiazide (Standard) is the analytical standard of Trichlormethiazide. This product is intended for research and analytical applications. Trichlormethiazide is an orally active thiazide diuretic, with antihypertensive effect. Trichlormethiazide increases urine volume (UV), Na and K excretion and tends to improve the depressed creatinine clearance (CCRE) in acute renal failure rats model .
    Trichlormethiazide (Standard)
  • HY-10450S5
    Dapagliflozin-13C6-1

    		Isotope-Labeled Compounds SGLT Metabolic Disease Cancer
    Dapagliflozin- 13C6-1 is 13C labeled Dapagliflozin. Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin induces HIF1 expression and attenuates renal IR injury .
    Dapagliflozin-13C6-1
  • HY-10450R
    Dapagliflozin (Standard)

    BMS-512148 (Standard)

    		 Reference Standards SGLT Metabolic Disease Cancer
    Dapagliflozin (Standard) is the analytical standard of Dapagliflozin. This product is intended for research and analytical applications. Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin induces HIF1 expression and attenuates renal IR injury .
    Dapagliflozin (Standard)
  • HY-W040047S
    Pregnanediol 3-glucuronide-13C5

    		Endogenous Metabolite Isotope-Labeled Compounds Endocrinology
    Pregnanediol 3-glucuronide is the main end-metabolite of Progesterone (HY-N0437). Pregnanediol 3-glucuronide is a metabolite of Progesterone formed by hydroxylation and glucuronidation in the liver, with high hydrophilicity and easy excretion through urine. Pregnanediol 3-glucuronide excretion rate of ≥ 9 μmol/24 h can serve as biochemical evidence of ovulation. Pregnanediol 3-glucuronide reflects the quality of the luteal phase, and a level of < 7 μmol/24 h may indicate anovulation or luteal insufficiency. Pregnanediol 3-glucuronide holds significant importance in monitoring female reproductive health, assessing pregnancy, and diagnosing endocrine disorders.
    Pregnanediol 3-glucuronide-13C5
  • HY-10450S3
    Dapagliflozin-13C6

    BMS-512148-13C6

    		 Isotope-Labeled Compounds Metabolic Disease Cancer
    Dapagliflozin- 13C6 (BMS-512148- 13C6) is 13C labeled Dapagliflozin. Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin induces HIF1 expression and attenuates renal IR injury .
    Dapagliflozin-13C6
  • HY-113465S
    Leukotriene E4-d5

    LTE4-d5

    		 Endogenous Metabolite Inflammation/Immunology
    Leukotriene E4-d5 is the deuterium labeled Leukotriene E4. Leukotriene E4 (LTE4) is produced by the action of dipeptidase on LTD4. Leukotriene E4 is one of the constituents of slow-reacting substance of anaphylaxis (SRS-A). Leukotriene E4 accumulates in both plasma and urine and urinary excretion of Leukotriene E4 is most often used as an indicator of asthma.
    Leukotriene E4-d5
  • HY-10450S2
    Dapagliflozin-d4

    BMS-512148-d4

    		 Isotope-Labeled Compounds SGLT Metabolic Disease Cancer
    Dapagliflozin-d4 (BMS-512148-d4) is deuterium labeled Dapagliflozin. Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin induces HIF1 expression and attenuates renal IR injury .
    Dapagliflozin-d4
  • HY-W040047
    Pregnanediol 3-glucuronide

    		Endogenous Metabolite Endocrinology
    Pregnanediol 3-glucuronide is the main end-metabolite of Progesterone (HY-N0437). Pregnanediol 3-glucuronide is a metabolite of Progesterone formed by hydroxylation and glucuronidation in the liver, with high hydrophilicity and easy excretion through urine. Pregnanediol 3-glucuronide excretion rate of ≥ 9 μmol/24 h can serve as biochemical evidence of ovulation. Pregnanediol 3-glucuronide reflects the quality of the luteal phase, and a level of < 7 μmol/24 h may indicate anovulation or luteal insufficiency. Pregnanediol 3-glucuronide holds significant importance in monitoring female reproductive health, assessing pregnancy, and diagnosing endocrine disorders .
    Pregnanediol 3-glucuronide
  • HY-P2281
    Atrial natriuretic factor (1-28) (human, porcine)

    Atrial natriuretic peptide (1-28)

    		 Endogenous Metabolite Cardiovascular Disease Metabolic Disease
    Atrial natriuretic factor (1-28) (human, porcine) exhibits blood pressure lowering activity by increasing sodium and urine excretion. Atrial natriuretic factor (1-28) (human, porcine) inhibits the release of pituitary adrenocorticotropic hormone (ACTH) and beta-endorphin through inhibition of pro-opiomelanocortin (POMC) expression. Atrial natriuretic factor (1-28) (human, porcine) increases cGMP levels in RMIC cells with an IC50 of 1.2 nM .
    Atrial natriuretic factor (1-28) (human, porcine)
  • HY-P2281A
    Atrial natriuretic factor (1-28) (human, porcine) TFA
    1 Publications Verification

    Atrial natriuretic peptide (1-28) TFA

    		 Endogenous Metabolite Cardiovascular Disease Metabolic Disease
    Atrial natriuretic factor (1-28) (human, porcine) TFA exhibits blood pressure lowering activity by increasing sodium and urine excretion. Atrial natriuretic factor (1-28) (human, porcine) TFA inhibits the release of pituitary adrenocorticotropic hormone (ACTH) and beta-endorphin through inhibition of pro-opiomelanocortin (POMC) expression. Atrial natriuretic factor (1-28) (human, porcine) TFA increases cGMP levels in RMIC cells with an IC50 of 1.2 nM .
    Atrial natriuretic factor (1-28) (human, porcine) TFA
  • HY-10450A
    Dapagliflozin ((2S)-1,2-propanediol, hydrate)
    Maximum Cited Publications
    57 Publications Verification

    BMS-512148 (2S)-1,2-propanediol, hydrate

    		 SGLT Metabolic Disease Cancer
    Dapagliflozin ((2S)-1,2-propanediol, hydrate) is the S-enantiomer of Dapagliflozin 1,2-propanediol, hydrate. Dapagliflozin ((2S)-1,2-propanediol, hydrate), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin ((2S)-1,2-propanediol, hydrate) induces HIF1 expression and attenuates renal IR injury .
    Dapagliflozin ((2S)-1,2-propanediol, hydrate)
  • HY-136182A
    YM-244769

    		Na+/Ca2+ Exchanger Cardiovascular Disease Neurological Disease
    YM-244769 is a potent, selective and orally active Na +/Ca 2+ exchanger (NCX) inhibitor. YM-244769 preferentially inhibits NCX3 and suppresses the unidirectional outward NCX current (Ca 2+ entry mode), with IC50s of 18 nM and 50 nM, respectively. YM-244769 efficiently protects against hypoxia/reoxygenation-induced SH-SY5Y neuronal cell damage. YM-244769 can also increase urine volume and urinary excretion of electrolytes in mice .
    YM-244769
  • HY-136182
    YM-244769 dihydrochloride

    		Na+/Ca2+ Exchanger Cardiovascular Disease Neurological Disease
    YM-244769 dihydrochloride is a potent, selective and orally active Na +/Ca 2+ exchanger (NCX) inhibitor. YM-244769 dihydrochloride preferentially inhibits NCX3 and suppresses the unidirectional outward NCX current (Ca 2+ entry mode), with IC50s of 18 nM and 50 nM, respectively. YM-244769 dihydrochloride efficiently protects against hypoxia/reoxygenation-induced SH-SY5Y neuronal cell damage. YM-244769 dihydrochloride can also increase urine volume and urinary excretion of electrolytes in mice .
    YM-244769 dihydrochloride
  • HY-107659
    YM-244769 hydrochloride

    		Na+/Ca2+ Exchanger Cardiovascular Disease Neurological Disease
    YM-244769 hydrochloride is a potent, selective and orally active Na +/Ca 2+ exchanger (NCX) inhibitor. YM-244769 hydrochloride preferentially inhibits NCX3 and suppresses the unidirectional outward NCX current (Ca 2+ entry mode), with IC50s of 18 nM and 50 nM, respectively. YM-244769 hydrochloride efficiently protects against hypoxia/reoxygenation-induced SH-SY5Y neuronal cell damage. YM-244769 hydrochloride can also increase urine volume and urinary excretion of electrolytes in mice .
    YM-244769 hydrochloride
  • HY-129397
    2,3-Dinor-11beta-prostaglandin F2alpha

    BPG; 2,3-Dinor-11β-PGF2α; 2,3-dinor-11-epi PGF2α

    		 Prostaglandin Receptor Endocrinology
    2,3-Dinor-11beta-prostaglandin F2alpha (2,3-Dinor-11β-PGF2α) is a metabolite of PGD2. Urinary excretion of 2,3-Dinor-11beta-prostaglandin F2alpha is increased in patients with mast cell activation disease (MCAD) and has been used as a marker of increased PGD2 levels. 2,3-Dinor-11beta-prostaglandin F2alpha levels are also increased in the urine of patients with asthma and are positively correlated with impaired lung function.
    2,3-Dinor-11beta-prostaglandin F2alpha
  • HY-102093A
    ZD 7155

    		Angiotensin Receptor Others
    ZD 7155 is an AT1R selective antagonist with renal function modulating activity. The effects of ZD 7155 on glomeruli and tubules were measured in 1- (N = 9) and 6-week-old (N = 13) lambs. Pretreatment with ZD 7155 after L-NAME infusion did not alter glomerular function in 1- or 6-week-old lambs. During postnatal development, Ang II modulates the effects of NO on electrolyte handling via AT1R and AT2R. In 6-week-old lambs, selective inhibition of AT1R and AT2R increased the excretion of Na+, K+, and Cl-. In 6-week-old lambs, pretreatment with ZD 7155 and PD 123319 followed by the addition of L-NAME increased urine flow rate by 200%, free water clearance by 50%, and decreased urine osmolality by 40%. The same trends of changes in these variables were also observed when L-NAME was added to ZD 7155 or PD 123319, although to a lesser extent.
    ZD 7155
  • HY-10450AR
    Dapagliflozin ((2S)-1,2-propanediol, hydrate) (Standard)

    BMS-512148 (2S)-1,2-propanediol, hydrate (Standard)

    		 Reference Standards SGLT Metabolic Disease Cancer
    Dapagliflozin ((2S)-1,2-propanediol, hydrate) (Standard) is the analytical standard of Dapagliflozin ((2S)-1,2-propanediol, hydrate). This product is intended for research and analytical applications. Dapagliflozin ((2S)-1,2-propanediol, hydrate) is the S-enantiomer of Dapagliflozin 1,2-propanediol, hydrate. Dapagliflozin ((2S)-1,2-propanediol, hydrate), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin ((2S)-1,2-propanediol, hydrate) induces HIF1 expression and attenuates renal IR injury .
    Dapagliflozin ((2S)-1,2-propanediol, hydrate) (Standard)
  • HY-118156
    L-699333

    		Others Others
    L-699333 is a 5-lipoxygenase (5-LO) inhibitor belonging to the thieno[2,3,4-cd]indole class. This compound has a 2-ethoxybutyric acid side chain and is a potent inhibitor of the biosynthesis of 5-HPETE and LTB4 produced from human 5-LO, with ICm values of 22 nM, 7 nM, and 3.8 pM for human neutrophils and whole blood, respectively. L-699333 has shown anti-inflammatory and antiasthmatic effects in a variety of animal models, including rat pleurisy models, antigen-induced wheezing models, and awake macaque and sheep asthma models. Its inhibition of 5-LO is highly selective, with higher ICm values or stronger competitive inhibition in FLAP binding assays compared to inhibition of human 15-LO, porcine 12-LO, and ram epididymal cyclooxygenase. The racemic enantiomer 14g of L-699333 is the most potent enantiomer to date, with inhibitory effects similar to those of the known MK-0591, which has been shown in clinical trials to inhibit the biochemical effects of LTB4 biosynthesis in vitro and LTE4 excretion in urine.
    L-699333

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: